Literature DB >> 808041

The disposition and metabolism of I.C.I. 58,834 (viloxazine) in animals.

D E Case, H Illston, P R Reeves, B Shuker, P Simons.   

Abstract

1. 2-(2-Ethoxyphenoxymethyl-2,3,5,6-tetrahydro-1,4-oxazine (I.C.I. 58,834) has been prepared in three different 14C-labelled forms and its absorption, distribution, metabolism and elimination studied in six animals species. 2. In all species I.C.I. 58,834 was well absorbed after oral administration and extensively metabolized. Excretion via the kidney was the main route of elimination. 3. In the rat the major metabolic pathway is o-dealkylation and sulphate conjugation; the dealkylated metabolite was detected in brain extracts. A novel type of polar metabolite was isolated from rat urine, apparently a conjugate with sulphate and hippurate. 4. The metabolic pathways in beagle dogs include hydroxylation of the phenyl ring (and subsequent conjugation), N-methylation, formation of the N-methyl-N-oxide, and oxidation of the oxazine ring. 5. Maximum blood levels of I.C.I. 58,834 in dogs were unchanged during eight weeks daily administration and the half-life was 2.5-3 h. I.C.I. 58,834 is the main component in dog blood. Rat serum contains mainly conjugates of dealkylated I.C.I. 58,834 and the parent compound is a minor component. 6. None of the metabolites has significant CNS activity and activity observed following administration of I.C.I. 58,834 is due primarily to the parent compound.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 808041     DOI: 10.3109/00498257509056096

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  5 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man.

Authors:  G Cocchiara; R Battaglia; P Pevarello; M Strolin Benedetti
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jul-Sep       Impact factor: 2.441

Review 3.  Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-06       Impact factor: 9.546

4.  Relationship between blood and cerebrospinal levels of the antidepressant agent viloxazine.

Authors:  O Elwan; H K Adam
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

Review 5.  Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Authors:  Robert L Findling; Shawn A Candler; Azmi F Nasser; Stefan Schwabe; Chungping Yu; Jennie Garcia-Olivares; Welton O'Neal; Jeffrey H Newcorn
Journal:  CNS Drugs       Date:  2021-05-18       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.